Pharmaceutical companies must incorporate pediatric research into their drug development plans, which can increase the time and cost of bringing a new drug to market. However, compliance with PREA can also open new markets and provide competitive advantages. Companies that successfully develop pediatric indications for their products can benefit from extended market exclusivity under the Best Pharmaceuticals for Children Act (BPCA), another key piece of legislation that complements PREA.
